Vanguard Group Inc Neu Base Therapeutics, Inc. Transaction History

Vanguard Group Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.17 - $0.39 $96,715 - $221,877	-568,916 Reduced 60.16%	376,758 $67,000
Q4 2022 Feb 10, 2023	SELL	$0.18 - $0.3 $20,408 - $34,014	-113,380 Reduced 10.71%	945,674 $179,000
Q1 2022 May 13, 2022	SELL	$1.26 - $2.95 $385,030 - $901,461	-305,580 Reduced 22.39%	1,059,054 $1.99 Million
Q4 2021 Feb 14, 2022	SELL	$2.6 - $4.18 $4,409 - $7,089	-1,696 Reduced 0.12%	1,364,634 $3.83 Million
Q3 2021 Nov 12, 2021	BUY	$3.27 - $4.76 $223,936 - $325,974	68,482 Added 5.28%	1,366,330 $4.93 Million

Q2 2021 Aug 13, 2021	BUY	$4.63 - $7.34 $6.01 Million - $9.53 Million	1,297,848 New	1,297,848 $6.22 Million

Ticker NBSE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,258,700
Description
NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as ...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.